Petrelintide: Roche's Amylin Analog for Weight Loss
Petrelintide is a long-acting amylin analog from Zealand and Roche delivering double-digit weight loss with mild GI side effects. Here's what the Phase 2 data show.
Medically Reviewed
Reviewed by Dr. James Chen, MD, PhD, FACE on June 18, 2026
Our medical review process ensures clinical accuracy and patient safety.
The obesity-drug race has spent three years asking how to push weight loss past the GLP-1 ceiling. Petrelintide reframes the question entirely: instead of stacking more incretin pathways onto semaglutide, it bypasses the GLP-1 receptor altogether and works through amylin — a separate satiety hormone with its own brainstem circuitry. Developed by Zealand Pharma and now partnered with Roche in a deal worth up to $5.3 billion, petrelintide is the most advanced standalone amylin analog in clinical development, and its Phase 2 readout has made it one of the most closely watched names in metabolic medicine. The pitch is not just weight loss, but a gentler side-effect profile and the prospect of preserving more muscle than GLP-1 monotherapy.
Evidence: "Petrelintide was well tolerated across all dose levels, with no serious or severe treatment-emergent adverse events and a mean half-life of approximately 10 days supporting once-weekly dosing." — Brændholt Olsen S, et al. Diabetes, Obesity and Metabolism. 2026. DOI: 10.1111/dom.70753
What Petrelintide Is — and Why Amylin Matters
Petrelintide (development code ZP8396) is a once-weekly, subcutaneously injected, long-acting amylin analog. Amylin is a 37-amino-acid peptide hormone co-secreted with insulin from pancreatic beta cells after a meal. It signals fullness by acting on amylin receptor complexes in the area postrema and nucleus of the solitary tract — the same hindbrain regions that govern nausea and meal termination — and then projects to the hypothalamus to regulate longer-term energy balance. Native amylin has a half-life of only a few minutes, so engineering a lipidated, protease-resistant version that survives a full week was the core technical achievement behind petrelintide.
This is a fundamentally different target from the GLP-1 receptor that semaglutide and tirzepatide engage. GLP-1 drugs suppress appetite partly through reward-driven, hedonic eating circuits and slow gastric emptying aggressively, which is a major reason they produce nausea, vomiting, and constipation. Amylin agonism leans more on physiological meal-termination signaling and appears to slow gastric emptying less, which is the mechanistic basis for its calmer gastrointestinal footprint.
Evidence: "Amylin enhances the satiating effect of food through direct action on amylin receptors in the area postrema, and a single subcutaneous dose of the amylin analog pramlintide significantly reduced ad libitum food intake in obese subjects." — Chapman I, et al. Diabetologia. 2005. DOI: 10.1007/s00125-005-1732-4
The amylin concept is not new — pramlintide (Symlin) has been an FDA-approved amylin analog for diabetes since 2005 — but it required mealtime dosing and produced only modest weight effects. Petrelintide is the first long-acting amylin analog engineered specifically for chronic weight management, and it sits at the front of a wave that now includes Eli Lilly's eloralintide and Novo Nordisk's cagrilintide.
The Phase 1b and ZUPREME-1 Data
Petrelintide's clinical story has moved fast. The first-in-human single- and multiple-ascending-dose program established the pharmacokinetics and a clean early safety signal, with the 16-week Phase 1b portion producing mean weight loss of up to 8.6% versus 1.7% for placebo. The gastrointestinal events that did occur were overwhelmingly mild, and only one participant discontinued for tolerability across the entire dose range.
The pivotal proof point arrived with ZUPREME-1, a 42-week Phase 2 trial in 493 adults with overweight or obesity (mean BMI ~37 kg/m², without type 2 diabetes), with topline results reported by Roche in March 2026 and detailed data presented at the American Diabetes Association Scientific Sessions in June 2026. The trial met its primary endpoint, and the headline numbers put petrelintide squarely in the conversation with established GLP-1 therapies.
The numbers that matter
| Endpoint (ZUPREME-1, Week 42) | Petrelintide (high dose) | Placebo |
|---|---|---|
| Mean weight loss | 10.7% | 1.7% |
| Nausea (any) | 19.6% | 6.2% |
| Vomiting | 3.0% | 6.2% |
| Discontinuation for GI events | 1.5% | — |
| Reached target maintenance dose | 88–98% | — |
| Waist circumference reduction | 7.9–10.8 cm | 4.3 cm |
| hs-CRP reduction | 17–41% | 6% |
Two figures stand out. First, weight loss had not clearly plateaued at 42 weeks, suggesting the full effect may be larger over the longer treatment windows used in Phase 3. Second, the tolerability profile is unusually quiet for a drug in this class: a 1.5% GI-driven discontinuation rate and nausea rates roughly a third of what high-dose semaglutide typically produces. The cardiometabolic readouts — meaningful reductions in waist circumference, high-sensitivity C-reactive protein, and triglycerides — point to genuine improvement in metabolic risk rather than weight loss alone.
Tolerability as the strategic wedge
Roche and Zealand have been explicit that tolerability, not peak weight loss, is petrelintide's differentiator. Real-world GLP-1 discontinuation rates are high, and nausea is a leading reason patients stop. A drug that delivers double-digit weight loss while most patients reach their target dose without dropping out could win on adherence even if its ceiling is a few points below tirzepatide. That thesis is what carried petrelintide into a Phase 3 program planned to begin in the second half of 2026.
How Petrelintide Compares to GLP-1 Drugs and Other Amylin Agonists
Petrelintide is not the only amylin analog in late-stage development, and the class as a whole is being positioned around a distinct value proposition. Selective amylin agonism appears, in preclinical work, to spare lean tissue more than GLP-1 or GLP-1/GIP agonism — a point of real clinical interest given the muscle-loss concerns that shadow the GLP-1 class.
Evidence: "Amylin analogues induce a more selective loss of fat mass relative to lean mass than GLP-1 or GLP-1/GIP co-agonists in preclinical models, supporting their potential for higher-quality weight loss." — Lutz TA. British Journal of Pharmacology. 2025. DOI: 10.1111/bph.70484
That lean-mass angle is why petrelintide is often discussed alongside efforts to preserve muscle on GLP-1 therapy. It has not yet been confirmed with body-composition data in humans, but it is the central scientific hypothesis the Phase 3 program is built to test.
| Drug | Class | Highest reported weight loss | Stage |
|---|---|---|---|
| Petrelintide | Amylin analog (monotherapy) | ~10.7% at 42 wks (Ph 2) | Entering Phase 3 |
| Cagrilintide | Amylin analog (monotherapy) | ~10.8% at 26 wks (Ph 2) | In CagriSema combo |
| Eloralintide (Lilly) | Selective amylin agonist | up to 20.1% at 48 wks (Ph 2) | Phase 2 complete |
| Semaglutide 2.4 mg | GLP-1 | ~15% at 68 wks (Ph 3) | Approved |
| Tirzepatide | GLP-1 + GIP | ~21% at 72 wks (Ph 3) | Approved |
The monotherapy comparison is instructive. Petrelintide's ~10.7% closely tracks cagrilintide's ~10.8% from its Phase 2 monotherapy trial, confirming that long-acting amylin analogs land in a consistent efficacy band on their own.
Evidence: "Cagrilintide at the highest dose produced a mean body-weight reduction of 10.8% at 26 weeks versus 3.0% with placebo, and was well tolerated in people with overweight and obesity." — Lau DCW, et al. The Lancet. 2021. DOI: 10.1016/S0140-6736(21)01751-7
Lilly's eloralintide is the outlier, reaching up to 20.1% in its Phase 2 trial — a reminder that not all amylin agonists behave identically and that selective receptor targeting may unlock higher monotherapy efficacy.
Evidence: "Eloralintide met its primary endpoint with mean weight reductions ranging from 9.5% to 20.1% across dose groups at 48 weeks, compared with 0.4% for placebo." — Billings LK, et al. The Lancet. 2025. DOI: 10.1016/S0140-6736(25)02155-5
What's Next: The Combination Bet and Phase 3
The most consequential part of Roche's strategy is not petrelintide as a standalone drug but petrelintide as a foundational therapy that can be paired with a GLP-1. The combination logic mirrors what made CagriSema compelling: amylin and GLP-1 act on complementary satiety circuits, so co-administration tends to be additive rather than redundant. Roche intends to combine petrelintide with its own GLP-1/GIP agonist, CT-388, in pursuit of best-in-class efficacy with the tolerability advantages of an amylin backbone.
Evidence: "Co-administration of a long-acting amylin analog with semaglutide engages distinct satiety pathways and produces additive reductions in body weight beyond either agent alone." — Frias JP, et al. The Lancet. 2023. DOI: 10.1016/S0140-6736(23)01163-7
The near-term milestones are concrete. ZUPREME-2, the Phase 2 trial in adults with overweight or obesity and type 2 diabetes, is expected to read out in the second half of 2026, and a Phase 3 chronic-weight-management program is slated to begin in the same window. Whether petrelintide ultimately competes as a gentler standalone option or as the amylin half of a next-generation combination, it represents the clearest sign yet that the obesity field is moving beyond GLP-1 monotherapy into multi-hormone strategies.
Evidence: "Amylin-based therapeutics represent an emergent and mechanistically distinct opportunity in obesity, with the potential to complement incretin agonists and improve the quality and tolerability of pharmacological weight loss." — Nat Rev Endocrinol. 2025. DOI: 10.1038/s41574-025-01125-9
Key Takeaways
- Petrelintide is a once-weekly long-acting amylin analog from Zealand Pharma and Roche, working through a satiety pathway entirely separate from GLP-1.
- Phase 2 ZUPREME-1 delivered ~10.7% weight loss at 42 weeks with weight loss still trending downward, alongside meaningful cardiometabolic improvements.
- Tolerability is the headline advantage: nausea rates roughly a third of high-dose GLP-1s and a 1.5% GI-driven discontinuation rate.
- The lean-mass-sparing hypothesis is promising but unproven in humans — it is the key question Phase 3 will answer.
- The real prize may be combinations: petrelintide is being positioned as a foundational amylin backbone to pair with a GLP-1/GIP agonist.
Petrelintide will not reach pharmacies imminently — Phase 3 is only beginning — but it has already shifted the strategic map of obesity medicine. For patients who cannot tolerate GLP-1 side effects, an amylin analog that matches much of the weight loss with far less nausea would be a genuinely new option rather than another variation on the same mechanism.
References
- Brændholt Olsen S, et al. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Petrelintide for Weight Management: Two Randomized, Controlled Phase 1 Trials. Diabetes, Obesity and Metabolism. 2026. DOI: 10.1111/dom.70753
- Lau DCW, Erichsen L, Francisco AM, et al. Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial. The Lancet. 2021;398(10317):2160-2172. DOI: 10.1016/S0140-6736(21)01751-7
- Billings LK, et al. Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial. The Lancet. 2025. DOI: 10.1016/S0140-6736(25)02155-5
- Frias JP, et al. Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial. The Lancet. 2023;402(10403):720-730. DOI: 10.1016/S0140-6736(23)01163-7
- Chapman I, Parker B, Doran S, et al. Effect of pramlintide on satiety and food intake in obese subjects and subjects with type 2 diabetes. Diabetologia. 2005;48(5):838-848. DOI: 10.1007/s00125-005-1732-4
- Lutz TA. Amylin analogues as a novel perspective in anti-obesity therapy. British Journal of Pharmacology. 2025. DOI: 10.1111/bph.70484
- Amylin: emergent therapeutic opportunities in overweight, obesity and diabetes mellitus. Nature Reviews Endocrinology. 2025. DOI: 10.1038/s41574-025-01125-9
Last updated: 2026-06-18 Medical review: Dr. James Chen, MD, PhD, FACE
Tags
Written By
Dr. Sarah Mitchell
Medical Director, MD, FACP
Dr. Sarah Mitchell is a board-certified internist specializing in metabolic medicine and weight management. With over 15 years of clinical experience, she has helped thousands of patients achieve sustainable weight loss through evidence-based approaches.
Medical Reviewer
Dr. James Chen
Endocrinologist, MD, PhD, FACE
Dr. James Chen is a fellowship-trained endocrinologist with expertise in diabetes, metabolism, and hormone-related weight disorders. His research on GLP-1 receptor agonists has been published in leading medical journals.
Editorial Standards
This article follows our strict editorial guidelines. All content is based on peer-reviewed research and reviewed by medical professionals. This information is for educational purposes only — always consult your healthcare provider before making medical decisions.